Biopharmaceutical company developing therapies for unmet medical needs
Vanda is a public biopharmaceutical company running a commercial-stage pipeline across Phase I–IV clinical studies while managing licensing, M&A, and partnership financial modeling. The hiring footprint is heavily skewed toward sales (114 roles) and healthcare (95 roles) relative to research (3), reflecting a company in late-stage development and market expansion rather than drug discovery. Pain points cluster around reimbursement access and sales performance—recurring friction suggesting complex payer relationships and a need for stronger field execution.
Vanda develops and commercializes pharmaceutical therapies targeting areas with significant unmet medical needs. The company operates across clinical development (ongoing Phase I–IV studies), regulatory compliance, and commercial operations. With 201–500 employees headquartered in Washington, DC, and hiring in the United States and United Kingdom, Vanda serves healthcare systems and payers. The business model combines product development (stability studies, assay design) with partnership and licensing activity (M&A transactions, financial modeling for partnerships).
Microsoft Office suite (Excel, Word, PowerPoint), SAS, R, Python, SQL, Salesforce, Power BI, and ArcGIS. The mix reflects both statistical/clinical work (SAS, R, SQL) and sales/business operations (Salesforce, Power BI).
Clinical trials (Phase I–IV), licensing and M&A transactions, stability and shelf-life studies, new assay design, and financial modeling for partnerships. Tax planning and pitch deck preparation also appear in active projects.
Other companies in the same industry, closest in size